Drug Profile
Research programme: anti-infectives - Arpida/Spexis
Alternative Names: Anti-infectives research programme - Arpida/Spexis; Research programme: antibacterials - Arpida/Spexis; Research programme: antifungals - Arpida/SpexisLatest Information Update: 16 Feb 2022
Price :
$50
*
At a glance
- Originator Arpida; Polyphor
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Bacterial infections; Mycoses
Most Recent Events
- 17 Apr 2008 Discontinued - Preclinical for Bacterial infections in European Union (unspecified route)
- 17 Apr 2008 Discontinued - Preclinical for Mycoses in European Union (unspecified route)
- 13 Nov 2003 Preclinical trials in Bacterial infections in Europe (unspecified route)